| Authors: |
Dowlati A; Department of Medicine Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA., Harvey RD; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Carvajal RD; Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons New York, New York, NY, USA., Hamid O; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Cedars-Sinai Affiliate, Los Angeles, CA, USA., Klempner SJ; Department of Medicine and Oncology, Massachusetts General Hospital, Boston, MA, USA., Kauh JSW; Medical Oncology, Hutchison MediPharma Inc., Florham Park, NJ, USA., Peterson DA; Eli Lilly and Company, Indianapolis, IN, USA., Yu D; Eli Lilly and Company, Indianapolis, IN, USA., Chapman SC; Eli Lilly and Company, Windlesham, Surrey, UK., Szpurka AM; Eli Lilly and Company, Indianapolis, IN, USA., Carlsen M; Eli Lilly and Company, Indianapolis, IN, USA., Quinlan T; Eli Lilly and Company, Indianapolis, IN, USA., Wesolowski R; Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1310D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Robert.Wesolowski@osumc.edu. |
